BioMarin Reports Detailed Phase 3 Data for Voxzogo in Hypochondroplasia
- Voxzogo (vosoritide), BioMarin's CNP analog, is already approved for achondroplasia, a common skeletal dysplasia.
- BioMarin released fuller Phase 3 CANOPY-HCH-3 data testing Voxzogo in hypochondroplasia, a related, milder dysplasia, following a topline win announced earlier in 2026.
- Over roughly a year, the placebo-controlled trial measured growth velocity, standing height and arm span, showing a statistically significant, meaningful improvement in growth velocity and gains in the other measures.
- Safety data were consistent with Voxzogo's known profile in achondroplasia, with no new safety signals.
- BioMarin has filed the data with the FDA and plans further global submissions, part of a push to broaden Voxzogo's indications amid growing competition in growth-disorder treatments.
Call it textbook lifecycle management rather than competitive defense. Voxzogo already faces real pressure — Ascendis' navepegritide and other CNP analogs are chasing the same achondroplasia franchise, and a hypochondroplasia label doesn't blunt that; it just adds a second, smaller revenue stream to an asset that's already peaked in its core market. The economics are attractive on paper: filing existing trial infrastructure and safety data into an adjacent, milder dysplasia costs a fraction of a new NDA, and hypochondroplasia's larger-but-more-fragmented population (diagnosis is messier, symptoms subtler) means slower uptake, not necessarily bigger dollars. The real signal here is strategic: BioMarin is sweating Voxzogo rather than betting big on new rare-disease R&D, which is defensible cash-flow management but not a growth story — durability of the skeletal-dysplasia franchise now hinges on regulatory execution, not scientific risk.
BioMarin dishes ph. 3 results as Voxzogo expansion push underway ↗